Exercise Training Attenuates Cirrhotic Cardiomyopathy

• Autor(a) principal: de Souza, Sérgio Luiz Borges [UNESP]
• Data de Publicação: 2020
• Outros Autores: Mota, Gustavo Augusto Ferreira [UNESP], Gregolin, Cristina Schmitt, do Nascimento, Milena, Luvizotto, Renata Azevedo Melo, Bazan, Silmeia Garcia Zanati [UNESP], Sugizaki, Mário Mateus, Barbisan, Luis Fernando [UNESP], Cicogna, Antonio Carlos [UNESP], do Nascimento, André Ferreira
• Tipo de documento: Artigo
• Idioma: eng
• Título da fonte: Repositório Institucional da UNESP
• Texto Completo: http://dx.doi.org/10.1007/s12265-020-09997-0; http://hdl.handle.net/11449/200270
• topic: Cardiac dysfunction; Cirrhotic cardiomyopathy; Exercise training; Liver cirrhosis; Thioacetamide

Cirrhotic cardiomyopathy is a condition where liver cirrhosis is associated with cardiac dysfunction. Triggers and blockers of cirrhotic cardiomyopathy are poorly understood, which might compromise the prognosis of chronic liver disease patients. We tested whether exercise training would reduce liver damage induced by thioacetamide and prevent liver cirrhosis-associated cardiomyopathy. Wistar rats were divided into three groups: control, thioacetamide (TAA), or TAA plus exercise. Thioacetamide increased liver weight and serum alanine aminotransferase and aspartate aminotransferase levels. Also, TAA treatment was involved with hepatic nodule formation, fibrotic septa, inflammatory infiltration, and hepatocyte necrosis. The exercise group presented with a reduction in liver injury status. We found that liver injury was associated with disordered cardiac hypertrophy as well as diastolic and systolic dysfunction. Exercise training attenuated cirrhosis-associated cardiac remodeling and diastolic dysfunction and prevented systolic impairment. These results provided insights that exercise training can mitigate cirrhotic cardiomyopathy phenotype. [Figure not available: see fulltext.].